$BCYC News
Last published 1w ago
- 1w agoBCYCBICYCLE THERAPEUTICS PLC - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoBCYCBicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial ResultsBusiness WireNuzefatide pevedotin granted FDA Orphan Drug Designation for the treatment of pancreatic cancer; further updates expected in 2027 Initiation of the first company-sponsored radioligand clinical trial for BT1702, an
- 3mo agoBCYCBicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial ResultsBusiness WireData presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities Expanded
- 5mo agoBCYCBicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual MeetingBusiness WireIn the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for
- 6mo agoBCYCBicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial ResultsBusiness WirePresentations at AACR Annual Meeting 2026 underscore significant opportunities for nuzefatide pevedotin in EphA2 expressing cancers, including pancreatic cancer Human imaging data provides further evidence of the
- 6mo agoBCYCBicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual MeetingBusiness WireBicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral
- 6mo agoBCYCBicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026Business WirePhase 1 combination data of 6.5mg/m2 Q2W nuzefatide pevedotin plus nivolumab demonstrate an encouraging preliminary efficacy profile with a differentiated tolerability profile in previously treated metastatic urothelial
- 7mo agoBCYCBicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026Business WireBicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral
- 7mo agoBCYCBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial ResultsBusiness WirePhase 2/3 Duravelo-2 pivotal trial evaluating zelenectide pevedotin (zelenectide) plus pembrolizumab in metastatic urothelial cancer (mUC) successfully identifies 6mg/m2 zelenectide two weeks on, one week off dose (6mg
- 9mo agoBCYCBicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology PipelineBusiness WireTravis Thompson appointed chief financial officer; to succeed Alethia Young Michael Method, M.D., MPH, MBA promoted to chief medical officer; to succeed Eric Westin, M.D. Michael Skynner, Ph.D., chief technology
- 11mo agoBCYCBicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical PipelineBusiness WireExecution of a 15-year contract including an option to renew with UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium (RepU), with the potential to deliver tens of thousands of
- 12mo agoBCYCBicycle Therapeutics to Participate in the Jefferies London Healthcare ConferenceBusiness WireBicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that
- 1y agoBCYCBicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial ResultsBusiness WireDose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies Enhanced clinical leadership team with
- 1y agoBCYCBicycle Therapeutics Plc (BCYC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoBCYCBicycle Therapeutics Strengthens Board of Directors with New AppointmentsBusiness WireRoger Dansey, M.D., formerly Pfizer and Seagen, and Hervé Hoppenot, of Incyte and formerly Novartis Oncology, bring extensive drug development and commercialization expertise Bicycle Therapeutics plc (NASDAQ:BCYC), a
- 1y agoBCYCBicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial ResultsBusiness WireContinued advancement across research and development pipeline, with key program updates expected in 2H 2025 Phase 1/2 Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer open
- 1y agoBCAXBCYCBOLDRice Biotech Launch Pad welcomes Carolyn Ng to external advisory boardPR NewswireThe Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology...
- 1y agoBCYCBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBicycle Therapeutics plc (NASDAQ:BCYC), today announced that on July 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified
- 1y agoBCYCBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBicycle Therapeutics plc (NASDAQ:BCYC), today announced that on June 2, 2025, the Compensation Committee of the company's Board of Directors granted to seven new employees inducement awards consisting of non-qualified
- 1y agoBCYCBicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual MeetingBusiness WireBicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster
- 1y agoBCYCBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBicycle Therapeutics plc (NASDAQ:BCYC), today announced that on May 1, 2025, the Compensation Committee of the company's Board of Directors granted to 13 new employees inducement awards consisting of non-qualified share
- 1y agoBCYCBicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial ResultsBusiness WireMultiple abstracts accepted for presentation at 2025 ASCO and AACR annual meetings underscore breadth of Bicycle® technology and potential of oncology pipeline Phase 1/2 Duravelo-3 trial for zelenectide pevedotin
- 1y agoBCYCBicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025Business WireData continue to validate the potential of MT1-MMP as a novel cancer target and further underscore the applicability of Bicycle® Radioconjugates (BRC®) for radiopharmaceutical imaging Data are representative
- 1y agoBCYCBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBicycle Therapeutics plc (NASDAQ:BCYC), today announced that on April 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified
- 1y agoBCYCBicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceBusiness WireBicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that
- 1y agoBCYCBicycle Therapeutics Announces New Board and Key Clinical Leadership AppointmentsBusiness WireFelix J. Baker, Ph.D., to become chairman of Board of Directors Alessandro Riva, M.D., joins Board of Directors and Fabrice André, M.D., Ph.D., joins Clinical Advisory Board Eric Westin, M.D., promoted to chief
- 1y agoBCYCBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBicycle Therapeutics plc (NASDAQ:BCYC), today announced that on March 3, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified
- 1y agoBCYCBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial ResultsBusiness WireUpdated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line metastatic urothelial cancer;
- 1y agoBCYCBicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceBusiness WireBicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that
- 1y agoBCYCBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBicycle Therapeutics plc (NASDAQ:BCYC), today announced that on February 3, 2025, the Compensation Committee of the company's Board of Directors granted to 18 new employees inducement awards consisting of non-qualified
- 1y agoBCYCBicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and MilestonesBusiness WireUpdated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line cisplatin-ineligible metastatic
- 1y agoBCYCBicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceBusiness WireBicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that
- 1y agoBCYCBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBicycle Therapeutics plc (NASDAQ:BCYC), today announced that on January 2, 2025, the Compensation Committee of the company's Board of Directors granted to 12 new employees inducement awards consisting of non-qualified
- 1y agoBCYCBicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene AmplificationBusiness WireTopline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies Dose selection and topline
- 1y agoBCYCBicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology ExpertsBusiness WireBicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the
- 1y agoBCYCBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBicycle Therapeutics plc (NASDAQ:BCYC), today announced that on December 2, 2024, the Compensation Committee of the company's Board of Directors granted to thirteen new employees inducement awards consisting of
- 1y agoBCYCBicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program UpdateBusiness WireAbstract outlines data showing enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer patients with NECTIN4 gene amplification Company to announce topline combination data
- 1y agoBCYCBicycle Therapeutics to Participate in the Jefferies London Healthcare ConferenceBusiness WireBicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that
- 2y agoBCYCBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBicycle Therapeutics plc (NASDAQ:BCYC), today announced that on November 1, 2024, the Compensation Committee of the company's Board of Directors granted to twelve new employees inducement awards consisting of
- 2y agoBCYCBicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial ResultsBusiness WirePresented updated clinical results across oncology pipeline, including a 45% overall response rate (ORR) for zelenectide pevedotin monotherapy and a 45% ORR for BT5528 6.5 mg/m2 every two weeks monotherapy, both in
- 2y agoBCYCBicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation RadiopharmaceuticalsBusiness WireFirst human imaging data validate the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrate positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical
- 2y agoBCYCBicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 CongressBusiness WireCompany to host conference call and webcast on Wednesday, Oct. 23, at 8 a.m. ET to review the data and outline radiopharmaceuticals strategy Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a
- 2y agoBCYCBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBicycle Therapeutics plc (NASDAQ:BCYC), today announced that on October 1, 2024, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of
- 2y agoBCYCBicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024Business WireUpdated monotherapy data for Nectin-4 targeting zelenectide pevedotin in metastatic urothelial cancer (mUC) showed a promising 45% overall response rate (ORR), 11.1 months median duration of response and a generally
- 2y agoBCYCBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBicycle Therapeutics plc (NASDAQ:BCYC), today announced that on September 3, 2024, the Compensation Committee of the company's Board of Directors granted to seven new employees inducement awards consisting of
- 2y agoBCYCBicycle Therapeutics to Participate in Upcoming Investor ConferencesBusiness WireBicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that
- 2y agoBCYCBicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial ResultsBusiness WireFour abstracts containing data updates across clinical pipeline accepted for poster presentation at ESMO Congress 2024 Focused R&D pipeline on clinical programs and research areas that have the highest potential
- 2y agoBCYCBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBicycle Therapeutics plc (NASDAQ:BCYC) today announced that on August 1, 2024, the Compensation Committee of the company's Board of Directors granted to seven new employees inducement awards consisting of non-qualified
- 2y agoBCYCBicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024Business WireBicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the
- 2y agoBCYCBicycle Therapeutics to Participate in Upcoming Investor ConferencesBusiness WireBicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that